The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Correction of Sickle Cell Disease in Transgenic Mouse Models by Gene Therapy
Abstract
Sickle cell disease (SCD) is caused by a single point mutation in the human betaA globin gene that results in the formation of an abnormal hemoglobin [HbS (alpha2betaS2)]. We designed a betaA globin gene variant that prevents HbS polymerization and introduced it into a lentiviral vector we optimized for transfer to hematopoietic stem cells and gene expression in the adult red blood cell lineage. Long-term expression (up to 10 months) was achieved, without preselection, in all transplanted mice with erythroid-specific accumulation of the antisickling protein in up to 52% of total hemoglobin and 99% of circulating red blood cells. In two mouse SCD models, Berkeley and SAD, inhibition of red blood cell dehydration and sickling was achieved with correction of hematological parameters, splenomegaly, and prevention of the characteristic urine concentration defect.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Replacing b 87 threonine (T) with Q (HbA T87Q ) and incorporating this gene into a lentiviral vector that was transferred into hematopoietic stem cells corrected the main features of sickle cell disease in transgenic mice.115”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [115]
In the citing paper
“After establishing that β-globin lentiviral vectors had successfully corrected models of β-thalassemia and sickle cell disease in mice, 17,18 we initiated a human clinical study of ex vivo gene therapy for the β-hemoglobinopathies”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [18]
Citations
Cites
Szer, J. (1999) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,353
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909
INGRAM, V. M. (1957) · Nature · doi:10.1038/180326a0 · Cited by 978
HIV-1 Genome Nuclear Import Is Mediated by a Central DNA Flap
Zennou, V., Petit, C., Guetard, D., Nerhbass, U., Montagnier, L., & Charneau, P. (2000) · Cell · doi:10.1016/s0092-8674(00)80828-4 · Cited by 833
The Molecular Basis of Blood Diseases.
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-6-950_3 · Cited by 632
The "beta-like-globin" gene domain in human erythroid cells.
Tuan, D., Solomon, W., Li, Q., & London, I. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6384 · Cited by 601
Self-citationMay, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567
Transgenic Knockout Mice with Exclusively Human Sickle Hemoglobin and Sickle Cell Disease
Pászty, C., Brion, C. M., Manci, E., Witkowska, H. E., Stevens, M. E., Mohandas, N., & Rubin, E. M. (1997) · Science · doi:10.1126/science.278.5339.876 · Cited by 467
Knockout-Transgenic Mouse Model of Sickle Cell Disease
Ryan, T. M., Ciavatta, D. J., & Townes, T. M. (1997) · Science · doi:10.1126/science.278.5339.873 · Cited by 300
Bender, M. A., Bulger, M., Close, J., & Groudine, M. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80433-5 · Cited by 224
Research works printed but not linked: 3
- R. L. Nagel M. H. Steinberg in Disorders of Hemoglobin: Genetics Pathophysiology and Clinical Management M. H. Steinberg B. G. Forget D. R. Higgs R. L. Nagel Eds. (Cambridge Univ. Press Cambridge 2001) pp. 711–756.
- Supplementary Web material is available on Science Online at www.sciencemag.org/cgi/content/full/294/5550/2368/DC1.
- We thank A. Bank and S. Goff for HIV components and critical review of the manuscript; R. M. Bookchin and Z. Etzion for Bayer-Technicon red cell analysis; S. Pack P. Rouyer-Fessard and S. Suzuka for expert technical assistance; R. Nancel for art work; Supported by NIH grant HL554352 (M.E.F. I.M.L. C.E. R.K.H R.L.N. P.L.) INSERM (Y.B. P.L.) and Association Française contre la Myopathie (Y.B. P.L.).
Cited by
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin
Hanna, J., Wernig, M., Markoulaki, S., Sun, C.-W., Meissner, A., Cassady, J. P., Beard, C., Brambrink, T., Wu, L.-C., Townes, T. M., et al. (2007) · Science · doi:10.1126/science.1152092 · Cited by 1,202
Kato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Self-citationStuart, M. J., & Nagel, R. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17192-4 · Cited by 819
Self-citationPlasticity of marrow-derived stem cells
Herzog, E. L., Chai, L., & Krause, D. S. (2003) · Blood · doi:10.1182/blood-2003-05-1664 · Cited by 830
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi, L. S., Benedicenti, F., Ambrosi, A., Di Serio, C., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1216 · Cited by 701
Gene therapy in a patient with sickle cell disease
Ribeil, J.-A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., Caccavelli, L., Neven, B., Bourget, P., El Nemer, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609677 · Cited by 696
Self-citationGene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Self-citationGENE THERAPY: Twenty-First Century Medicine
Verma, I. M., & Weitzman, M. D. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.050304.091637 · Cited by 616
Fetal hemoglobin in sickle cell anemia
Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., & Steinberg, M. H. (2011) · Blood · doi:10.1182/blood-2011-03-325258 · Cited by 553
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease
Bernaudin, F., Socie, G., Kuentz, M., Chevret, S., Duval, M., Bertrand, Y., Vannier, J.-P., Yakouben, K., Thuret, I., Bordigoni, P., et al. (2007) · Blood · doi:10.1182/blood-2007-03-079665 · Cited by 515
“Median ferritin level, ng/mL (range) 374 (13-3820) 792 (340-2059) 604 (31-3171) 553 (13-3820)”
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease
Kanter, J., Walters, M. C., Krishnamurti, L., Mapara, M. Y., Kwiatkowski, J. L., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Pierciey, F. J., Bonner, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117175 · Cited by 442
Side effects of retroviral gene transfer into hematopoietic stem cells
Baum, C., Düllmann, J., Li, Z., Fehse, B., Meyer, J., Williams, D. A., & von Kalle, C. (2003) · Blood · doi:10.1182/blood-2002-07-2314 · Cited by 435
Polymer systems for gene delivery—Past, present, and future
Wong, S. Y., Pelet, J. M., & Putnam, D. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.007 · Cited by 427
Sickle cell disease: old discoveries, new concepts, and future promise
Frenette, P. S., & Atweh, G. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30920 · Cited by 400
Ex vivo gene transfer and correction for cell-based therapies
Naldini, L. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2985 · Cited by 358
“In addition, certain applications strictly require switching on expression — and reaching very high expression levels — at only the proper stage of differentiation, such as in the case of globin transgenes used for HSC gene therapy of β-thalassaemi”
BackgroundKim, M.-H., Na, H.-K., Kim, Y.-K., Ryoo, S.-R., Cho, H. S., Lee, K. E., Jeon, H., Ryoo, R., & Min, D.-H. (2011) · ACS Nano · doi:10.1021/nn103130q · Cited by 364
Mutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors
Baum, C., Kustikova, O., Modlich, U., Li, Z., & Fehse, B. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.253 · Cited by 360
Gene delivery by lentivirus vectors
Cockrell, A. S., & Kafri, T. (2007) · Molecular Biotechnology · doi:10.1007/s12033-007-0010-8 · Cited by 355
“demonstrating efficient transduction of human HSCs with lentiviral vectors [195], several researchers have reported successful correction of genetic disorders in preclinical animal models, including immunodeficiencies and various hemoglobin disorders [54, 196–203].”
HIF-1–dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia
Eltzschig, H. K., Abdulla, P., Hoffman, E., Hamilton, K. E., Daniels, D., Schönfeld, C., Löffler, M., Reyes, G., Duszenko, M., Karhausen, J., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050177 · Cited by 351
“The HIV-1 lentiviral vector used was based on a vector previously described in detail ( 41 ).”
MethodSelf-citationSilencing and Variegation of Gammaretrovirus and Lentivirus Vectors
Ellis, J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1241 · Cited by 379
Self-citationHIF‐dependent induction of adenosine A2B receptor in hypoxia
Kong, T., Westerman, K. A., Faigle, M., Eltzschig, H. K., & Colgan, S. P. (2006) · The FASEB Journal · doi:10.1096/fj.06-6419com · Cited by 335
“The HIV-1 lentiviral vector used was based on a vector previously described in detail (41).”
Self-citationLentiviral vectors: basic to translational
Sakuma, T., Barry, M. A., & Ikeda, Y. (2012) · Biochemical Journal · doi:10.1042/bj20120146 · Cited by 336
Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing
Xu, J., Peng, C., Sankaran, V. G., Shao, Z., Esrick, E. B., Chong, B. G., Ippolito, G. C., Fujiwara, Y., Ebert, B. L., Tucker, P. W., et al. (2011) · Science · doi:10.1126/science.1211053 · Cited by 326
Correction of sickle cell disease by homologous recombination in embryonic stem cells
Wu, L.-C., Sun, C.-W., Ryan, T. M., Pawlik, K. M., Ren, J., & Townes, T. M. (2006) · Blood · doi:10.1182/blood-2006-02-004812 · Cited by 327
Steinberg, M. H. (2008) · The Scientific World JOURNAL · doi:10.1100/tsw.2008.157 · Cited by 293
“Gene therapy has “cured” sickle cell disease and thalassemia in mice engineered to have these disorders[229,230].”
BackgroundBaroreceptor reflex pathways and neurotransmitters: 10 years on
Pilowsky, P. M., & Goodchild, A. K. (2002) · Journal of Hypertension · doi:10.1097/00004872-200209000-00002 · Cited by 289
Anemia: progress in molecular mechanisms and therapies
Sankaran, V. G., & Weiss, M. J. (2015) · Nature Medicine · doi:10.1038/nm.3814 · Cited by 281
Gene Therapy with Viral Vectors
Kootstra, N. A., & Verma, I. M. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140257 · Cited by 267
Rivella, S., May, C., Chadburn, A., Rivière, I., & Sadelain, M. (2003) · Blood · doi:10.1182/blood-2002-10-3305 · Cited by 220
Ye, L., Chang, J. C., Lin, C., Sun, X., Yu, J., & Kan, Y. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904689106 · Cited by 216
Stocker, J. W., De Franceschi, L., McNaughton-Smith, G. A., Corrocher, R., Beuzard, Y., & Brugnara, C. (2003) · Blood · doi:10.1182/blood-2002-05-1433 · Cited by 206
Self-citationGenetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease
Hoban, M. D., Orkin, S. H., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2015-09-618587 · Cited by 194
“alone from a lentiviral vector resulted in pancellular, erythroidspecific expression in a murine model of SCD at levels capable of correcting the disease pathophysiology.(51) Lentiviral expression of a triple-mutant b-globin (G16D, E22A, and T87Q) with increased affinity for a-globin subunits (so-called bAS3) also cor…”
BackgroundLevasseur, D. N., Ryan, T. M., Pawlik, K. M., & Townes, T. M. (2003) · Blood · doi:10.1182/blood-2003-04-1251 · Cited by 195
Viral Vectors in Gene Therapy: Where Do We Stand in 2023?
Lundstrom, K. (2023) · Viruses · doi:10.3390/v15030698 · Cited by 187
“…mutation in the β‐ globin chain of the adult α 2 β 2 hemoglobin tetramer [213], HSCs transduced with LV vectors expressing a β A ‐ globin variant have demonstrated long ‐ term expression for 10 months and accumulation of anti ‐ sickling protein up to 52% of total hemoglobin in mouse models [191].”
Imren, S., Payen, E., Westerman, K. A., Pawliuk, R., Fabry, M. E., Eaves, C. J., Cavilla, B., Wadsworth, L. D., Beuzard, Y., Bouhassira, E. E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212507099 · Cited by 188
Self-citationPiel, F. B., Rees, D. C., DeBaun, M. R., Nnodu, O., Ranque, B., Thompson, A. A., Ware, R. E., Abboud, M. R., Abraham, A., Ambrose, E. E., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00096-0 · Cited by 177
Therapeutic strategies for sickle cell disease: towards a multi-agent approach
Telen, M. J., Malik, P., & Vercellotti, G. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0003-2 · Cited by 181
Successful correction of the human β-thalassemia major phenotype using a lentiviral vector
Puthenveetil, G., Scholes, J., Carbonell, D., Qureshi, N., Xia, P., Zeng, L., Li, S., Yu, Y., Hiti, A. L., Yee, J.-K., et al. (2004) · Blood · doi:10.1182/blood-2004-04-1427 · Cited by 182
Sickle Cell Disease: New Opportunities and Challenges in Africa
Makani, J., Ofori-Acquah, S. F., Nnodu, O., Wonkam, A., & Ohene-Frempong, K. (2013) · The Scientific World Journal · doi:10.1155/2013/193252 · Cited by 175
“This has been done successfully in the sickle transgenic mouse [163], but progress in humans has been limited by identification of appropriate vectors and efficacy for gene transfer and low level expression of globin genes.”
BackgroundBiosafety Features of Lentiviral Vectors
Schambach, A., Zychlinski, D., Ehrnstroem, B., & Baum, C. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.229 · Cited by 173
“The most prominent example for this is the successful transduction of complex globin expression cassettes, which contain larger pieces of regulatory DNA and introns (May et al., 2000; Pawliuk et al., 2001; Roselli et al., 2010).”
A Phase I/II Clinical Trial of β‐Globin Gene Therapy for β‐Thalassemia
BANK, A., DORAZIO, R., & LEBOULCH, P. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1345.007 · Cited by 169
Self-citationLineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.
Brendel, C., Guda, S., Renella, R., Bauer, D. E., Canver, M. C., Kim, Y.-J., Heeney, M. M., Klatt, D., Fogel, J., Milsom, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87885 · Cited by 167
Erythropoiesis: insights into pathophysiology and treatments in 2017
Zivot, A., Lipton, J. M., Narla, A., & Blanc, L. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0011-z · Cited by 163
Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β A(T87Q) - Globin Gene
Negre, O., Eggimann, A.-V., Beuzard, Y., Ribeil, J.-A., Bourget, P., Borwornpinyo, S., Hongeng, S., Hacein-Bey, S., Cavazzana, M., Leboulch, P., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.007 · Cited by 159
“With respect to SCD, one can surmise that the antisickling properties of b-globin will be comparable to or slightly lower than that of cglobin.(65) HPFH with HbF levels of 30% or even lower are consistently associated with complete absence of clinical and biological signs of SCD in otherwise homozygous b/b patients, w…”
BackgroundSelf-citationMa, N., Liao, B., Zhang, H., Wang, L., Shan, Y., Xue, Y., Huang, K., Chen, S., Zhou, X., Chen, Y., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.496174 · Cited by 158
“Recently, the development of gene therapy based on viral transduction of a normal HBB gene into a patient’s own hematopoietic stem cells raised hopes for those who do not have access to bone marrow transplantation (3, 4).”
BackgroundHanawa, H., Hematti, P., Keyvanfar, K., Metzger, M. E., Krouse, A., Donahue, R. E., Kepes, S., Gray, J., Dunbar, C. E., Persons, D. A., et al. (2004) · Blood · doi:10.1182/blood-2004-01-0045 · Cited by 159
Sickle Cell Anaemia: Progress in Pathogenesis and Treatment
Ballas, S. K. (2002) · Drugs · doi:10.2165/00003495-200262080-00003 · Cited by 181
“Research in this area has advanced at a faster rate than previously expected and gene therapy may be available for trial in selected patients with sickle cell disease in the near future.[162]”
Persons, D. A., Hargrove, P. W., Allay, E. R., Hanawa, H., & Nienhuis, A. W. (2003) · Blood · doi:10.1182/blood-2002-07-2211 · Cited by 162
“24, one unique 2–vector copy clone (24-39) was identified that demonstrated high-level staining for -globin (Figure 7B, right panel).”
BackgroundMiccio, A., Cesari, R., Lotti, F., Rossi, C., Sanvito, F., Ponzoni, M., Routledge, S. J. E., Chow, C.-M., Antoniou, M. N., & Ferrari, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711666105 · Cited by 166
Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now
Hsieh, M. M., Fitzhugh, C. D., & Tisdale, J. F. (2011) · Blood · doi:10.1182/blood-2011-01-332510 · Cited by 167
Xu, P., Tong, Y., Liu, X., Wang, T., Li, C., Wang, B.-Y., Lv, X., Huang, Y., & Liu, D. (2015) · Scientific Reports · doi:10.1038/srep12065 · Cited by 170
“Gene therapy in which a normal HBB gene is provided to a patient’s own HSCs via viral transduction is a potential treatment for β -thalassemia 11,12 .”
Ramezani, A., Hawley, T. S., & Hawley, R. G. (2003) · Blood · doi:10.1182/blood-2002-09-2991 · Cited by 162
Gene Therapy for Severe Combined Immunodeficiency
Cavazzana, M., Lagresle‐Peyrou, C., Hacein‐Bey‐Abina, S., & Fischer, A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.090203.104142 · Cited by 146
Sickle Cell Disease and the Eye: Old and New Concepts
Elagouz, M., Jyothi, S., Gupta, B., & Sivaprasad, S. (2010) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2009.11.004 · Cited by 142
Stable RNA interference: Comparison of U6 and H1 promoters in endothelial cells and in mouse brain
Mäkinen, P. I., Koponen, J. K., Kärkkäinen, A., Malm, T. M., Pulkkinen, K. H., Koistinaho, J., Turunen, M. P., & Ylä‐Herttuala, S. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.860 · Cited by 134
“the nervous system [10,21], hematopoietic cells [22,23], liver [24,25] and cardiomyocytes [26].”
BackgroundFetal hemoglobin in sickle cell anemia
Steinberg, M. H. (2020) · Blood · doi:10.1182/blood.2020007645 · Cited by 136
Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease
Sun, N., Liang, J., Abil, Z., & Zhao, H. (2012) · Molecular BioSystems · doi:10.1039/c2mb05461b · Cited by 159
Yao, S., Sukonnik, T., Kean, T., Bharadwaj, R. R., Pasceri, P., & Ellis, J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.04.007 · Cited by 138
“Attempts to overcome silencing by increasing the copy number [17] have an increased risk of insertional activation [35,36].”
BackgroundSelf-citationSickle‐cell haemoglobin polymerization: is it the primary pathogenic event of sickle‐cell anaemia?
Vekilov, P. G. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06794.x · Cited by 137
“Significantly, two features of the disease, red cell dehydration and the count of irreversibly sickled cells, sometimes considered as independent factors for the disease, were also reduced (Pawliuk et al, 2001).”
BackgroundMethodInfluentialKanter, J., Thompson, A. A., Pierciey, F. J., Hsieh, M., Uchida, N., Leboulch, P., Schmidt, M., Bonner, M., Guo, R., Miller, A., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26741 · Cited by 134
“The autologous HSPCs are transduced with the BB305 lentiviral vector (LVV) encoding the modified β-globin gene (β), which results in the production of anti-sickling hemoglobin (HbA).(11,12) By utilizing autologous transplantation, lovo-cel all but eliminates two important limitations of allogeneic transplantation, GVH…”
MethodSelf-citationImren, S., Fabry, M. E., Westerman, K. A., Pawliuk, R., Tang, P., Rosten, P. M., Nagel, R. L., Leboulch, P., Eaves, C. J., & Humphries, R. K. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21838 · Cited by 144
Self-citationGene Therapy for β-Hemoglobinopathies
Cavazzana, M., Antoniani, C., & Miccio, A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.024 · Cited by 149
Persons, D. A., Allay, E. R., Sawai, N., Hargrove, P. W., Brent, T. P., Hanawa, H., Nienhuis, A. W., & Sorrentino, B. P. (2003) · Blood · doi:10.1182/blood-2003-03-0677 · Cited by 130
Lentiviral vectors, two decades later
Naldini, L., Trono, D., & Verma, I. M. (2016) · Science · doi:10.1126/science.aah6192 · Cited by 136
Lignin Nanotubes As Vehicles for Gene Delivery into Human Cells
Ten, E., Ling, C., Wang, Y., Srivastava, A., Dempere, L. A., & Vermerris, W. (2013) · Biomacromolecules · doi:10.1021/bm401555p · Cited by 131
Emerging genetic therapy for sickle cell disease
Orkin, S. H., & Bauer, D. E. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041817-125507 · Cited by 119
Gene therapy for sickle cell disease: An update
Demirci, S., Uchida, N., & Tisdale, J. F. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.04.003 · Cited by 165
“Mutation in the sequence of β-globin (β) provided strong antisickling properties as efficient as γ-globin in reversing the phenotype in two relevant SCD mouse models, BERK and SAD [36].”
BackgroundTwo-Step Mechanism of Homogeneous Nucleation of Sickle Cell Hemoglobin Polymers
Galkin, O., Pan, W., Filobelo, L. F., Hirsch, R. E., Nagel, R. L., & Vekilov, P. G. (2007) · Biophysical Journal · doi:10.1529/biophysj.106.103705 · Cited by 115
“On the other hand, experiments with transgenic sickle cell mouse reconfirm that the primary pathogenic event of the disease is HbS polymerization: when polymerization was delayed, the mice were cured (80).”
BackgroundSelf-citationEmery, D. W., Yannaki, E., Tubb, J., Nishino, T., Li, Q., & Stamatoyannopoulos, G. (2002) · Blood · doi:10.1182/blood-2002-01-0219 · Cited by 123
Perumbeti, A., Higashimoto, T., Urbinati, F., Franco, R. S., Meiselman, H. J., Witte, D. P., & Malik, P. (2009) · Blood · doi:10.1182/blood-2009-01-201863 · Cited by 115
Samakoglu, S., Lisowski, L., Budak-Alpdoǧan, T., Usachenko, Y., Acuto, S., Marzo, R. D., Maggio, A., Zhu, P., Tisdale, J. F., Rivière, I., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1176 · Cited by 122
“The gene therapy approaches proposed to date are based on globin gene transfe”
MethodHanawa, H., Hargrove, P. W., Kepes, S., Srivastava, D. K., Nienhuis, A. W., & Persons, D. A. (2004) · Blood · doi:10.1182/blood-2004-03-0863 · Cited by 123
Harnessing HIV for therapy, basic research and biotechnology
Wiznerowicz, M., & Trono, D. (2004) · Trends in biotechnology · doi:10.1016/j.tibtech.2004.11.001 · Cited by 124
“Similar results have been obtained in a mouse model of sickle cell disease [ 32 ].”
ResultScalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines
Manceur, A. P., Kim, H. S., Misic, V., Andreev, N., Dorion-Thibaudeau, J., Lanthier, S., Bernier, A., Tremblay, S., Gélinas, A.-M., Broussau, S., et al. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.086 · Cited by 124
Lentiviral Vectors for Gene Delivery into Cells
Quinonez, R. A., & Sutton, R. E. (2002) · DNA and Cell Biology · doi:10.1089/104454902762053873 · Cited by 132
Hargrove, P. W., Kepes, S., Hanawa, H., Obenauer, J. C., Pei, D., Cheng, C., Gray, J. T., Neale, G. A. M., & Persons, D. A. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300394 · Cited by 119
β-globin gene transfer to human bone marrow for sickle cell disease
Romero, Z. G., Urbinati, F., Geiger, S., Cooper, A. R., Wherley, J., Kaufman, M. L., Hollis, R. P., de Assín, R. R., Senadheera, S., Sahagian, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67930 · Cited by 124
“vectors are reduced compared with those of vectors bearing simpler cassettes (17, 18).”
Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial
Magrin, E., Semeraro, M., Hebert, N., Joseph, L., Magnani, A., Chalumeau, A., Gabrion, A., Roudaut, C., Marouene, J., Lefrère, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01650-w · Cited by 118
Self-citationBiju, K. C., Zhou, Q., Li, G., Imam, S. Z., Roberts, J. L., Morgan, W. W., Clark, R. A., & Li, S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.107 · Cited by 106
Pathophysiology and therapy for haemoglobinopathies; Part I: sickle cell disease
Madigan, C., & Malik, P. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406010659 · Cited by 126
Retrovirus Vectors: Toward the Plentivirus?
Baum, C., Schambach, A., Bohne, J., & Galla, M. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.007 · Cited by 124
“Hence, this may facilitate the generation of vector particles containing complex expression cassettes that otherwise would be subject to bpregenome splicingQ [44,45].”
BackgroundPestina, T. I., Hargrove, P. W., Jay, D. W., Gray, J. T., Boyd, K. L., & Persons, D. A. (2008) · Molecular Therapy · doi:10.1038/mt.2008.259 · Cited by 110
RNAi: a potential new class of therapeutic for human genetic disease
Seyhan, A. A. (2011) · Human Genetics · doi:10.1007/s00439-011-0995-8 · Cited by 112
Advances in the Treatment of Sickle Cell Disease
Kapoor, S., Little, J. A., & Pecker, L. H. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.001 · Cited by 153
Current and future alternative therapies for beta-thalassemia major
Dreuzy, E. D., Bhukhai, K., Leboulch, P., & Payen, E. (2016) · Biomedical Journal · doi:10.1016/j.bj.2015.10.001 · Cited by 114
“gene, choosing instead to work with a variant we constructed, with an enhanced ability to inhibit HbS polymerization [141].”
BackgroundSelf-citationWilber, A. C., Hargrove, P. W., Kim, Y., Riberdy, J. M., Sankaran, V. G., Papanikolaou, E., Georgomanoli, M., Anagnou, N. P., Orkin, S. H., Nienhuis, A. W., et al. (2010) · Blood · doi:10.1182/blood-2010-08-300723 · Cited by 107
Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies
Magrin, E., Miccio, A., & Cavazzana, M. (2019) · Blood · doi:10.1182/blood.2019000949 · Cited by 114
Dangerous liaisons: the role of “danger” signals in the immune response to gene therapy
Brown, B. D., & Lillicrap, D. (2002) · Blood · doi:10.1182/blood-2001-11-0067 · Cited by 107
Koponen, J., Kankkonen, H. M., Kannasto, J., Wirth, T., Hillen, W., Bujard, H., & Ylä‐Herttuala, S. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301889 · Cited by 110
Mechanisms of Homogeneous Nucleation of Polymers of Sickle Cell Anemia Hemoglobin in Deoxy State
Galkin, O., & Vekilov, P. G. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.12.019 · Cited by 95
“The disease is caused by an A-to-T mutation within the sixth codon of the b-globin coding region.(3) As a result, the glutamic acid residues at the sixth position of the two b-subchains are replaced by non-polar valine.”
BackgroundGene therapy of inherited diseases
Fischer, A., & Cavazzana, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60874-0 · Cited by 112
Ailles, L., Schmidt, M., de Sio, F. R. S., Glimm, H., Cavalieri, S., Bruno, S., Piacibello, W., Kalle, C. V., & Naldini, L. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0720 · Cited by 98
Gene therapy for sickle cell disease: moving from the bench to the bedside
Abraham, A., & Tisdale, J. F. (2021) · Blood · doi:10.1182/blood.2019003776 · Cited by 110
Advances in lentiviral vector design for gene-modification of hematopoietic stem cells
Logan, A. C., Lutzko, C., & Kohn, D. B. (2002) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00346-4 · Cited by 110
Chang, A. H., & Sadelain, M. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300060 · Cited by 97
Pfeifer, A. (2004) · Transgenic Research · doi:10.1007/s11248-004-2735-5 · Cited by 87
Gene therapy of hemoglobinopathies: progress and future challenges
Ikawa, Y., Miccio, A., Magrin, E., Kwiatkowski, J. L., Rivella, S., & Cavazzana, M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz172 · Cited by 86
“globin) at much higher levels proved efficacious in correcting two mouse models of β-thalassemia (28,30,31) and SCD (29), paving the way to clinical trials.”
BackgroundNew therapies in sickle cell disease
Vichinsky, E. P. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09776-3 · Cited by 86
Metadata
- Authors
- Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., Humphries, R. K., Beuzard, Y., Nagel, R. L., & Leboulch, P.
- Affiliations
- Harvard–MIT Division of Health Sciences and Technology (US)
- Albert Einstein College of Medicine (US)
- Inserm (FR)
- Hospital for Sick Children (CA)
- University of British Columbia (CA)
- Brigham and Women's Hospital (US)
- Corresponding author
- Leboulch, Philippe
- ORCID
- Venue
- Science
- Published
- 2001-12-14
- Volume
- 294
- Issue
- 5550
- Pages
- 2368-2371
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2111444354
- Semantic Scholar
- 8478aea66daadff3ca4dac81dd340b3bafdacdc1
- Cited by
- 579
- References
- 33
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 13 · 2023: 22 · 2022: 13 · 2021: 15 · 2020: 18 · 2019: 13 · 2018: 31 · 2017: 19 · 2016: 23 · 2015: 14 · 2014: 17 · 2013: 18 · 2012: 22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL554352)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- sickle cell disease, beta-globin gene, lentiviral vectors, hematopoietic stem cell gene therapy, transgenic mouse model, erythroid-specific gene expression, splenomegaly, red blood cell dehydration
- MeSH terms
- Anemia, Sickle Cell, Animals, Disease Models, Animal, Erythrocytes, Genetic Vectors, Globins, Hematopoietic Stem Cells, Hemoglobin, Sickle, Humans, Mice, Inbred C57BL, Mice, Transgenic, Oxyhemoglobins, RNA, Messenger, Thalassemia, Transduction, Genetic, Genetic Therapy, HIV-1, Gene Expression, Lentivirus, Hematopoietic Stem Cell Transplantation, Transgenes, Locus Control Region, Mice, beta-Globins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.